EQUILLIUM, INC. Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings
EQUILLIUM, INC. (EQ) reported Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings of $0 for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings · last filed 2024-05-09
- EQUILLIUM, INC. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for the quarter ending 2024-03-31 was $0.00.
- EQUILLIUM, INC. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for the quarter ending 2023-12-31 was $0.00.
- EQUILLIUM, INC. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for the quarter ending 2023-09-30 was $0.00.
- EQUILLIUM, INC. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for the quarter ending 2023-06-30 was $0.00.
- EQUILLIUM, INC. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for fiscal 2023 was $0.00.
- EQUILLIUM, INC. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for fiscal 2022 was $0.00.
- EQUILLIUM, INC. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for fiscal 2021 was $0.00.
- EQUILLIUM, INC. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for fiscal 2020 was $0.00.
| Period end | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings 3 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings 6 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings 9 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings 12 month |
|---|---|---|---|---|
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | $0.00 derived: sum of 2 quarters · filed 2024-05-09 | $0.00 derived: sum of 3 quarters · filed 2024-05-09 | $0.00 derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $0.00 derived: sum of 2 quarters · filed 2024-03-25 | $0.00 derived: sum of 3 quarters · filed 2024-03-25 | $0.00 10-K · filed 2024-03-25 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | $0.00 derived: sum of 4 quarters · filed 2024-03-25 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | $0.00 derived: sum of 3 quarters · filed 2024-03-25 | $0.00 derived: sum of 4 quarters · filed 2024-03-25 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 | $0.00 derived: sum of 2 quarters · filed 2024-03-25 | $0.00 derived: sum of 3 quarters · filed 2024-03-25 | $0.00 derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $0.00 derived: sum of 2 quarters · filed 2024-03-25 | $0.00 derived: sum of 3 quarters · filed 2024-03-25 | $0.00 10-K · filed 2024-03-25 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | $0.00 derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | $0.00 derived: sum of 3 quarters · filed 2023-08-09 | $0.00 derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | $0.00 derived: sum of 2 quarters · filed 2023-05-11 | $0.00 derived: sum of 3 quarters · filed 2023-05-11 | $0.00 derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $0.00 derived: sum of 2 quarters · filed 2023-03-23 | $0.00 derived: sum of 3 quarters · filed 2023-03-23 | $0.00 10-K · filed 2023-03-23 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $0.00 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |